You can also read the IBTA e-News October 2019 edition in full online here.
Some of the highlights from this month's round-up:
- International Brain Tumour Awareness Week runs from 26th October to 2nd November. The global brain tumour community is marking International Brain Tumour Awareness Week with special activities around the world.
- The International Brain Tumour Alliance held its fourth biennial World Summit of Brain Tumour Patients Advocates at the National Institutes of Health in Bethesda, Maryland, USA from 9th to 12th October. The World Summit welcomed 95 participants from 25 countries and five continents – all with one dream: to significantly improve outcomes for brain tumour patients through greater collaboration, greater knowledge and greater hope.
- A team of UK researchers has published a paper in Nature Communications explaining how infrared light can be used to create a "bio-signature" of a person’s blood sample and scanned for signs of cancer using artificial intelligence algorithms. The test correctly identified brain cancer 87% of the time in a cohort of 104 people.
- A new study has shown that 5-ALA may also help doctors safely diagnose a brain tumour and monitor its response to treatment. The study, published in The Lancet’s EBioMedicine showed that, in the presence of 5-ALA, brain cancer cells not only become fluorescent but also secrete fluorescent particles called extracellular vesicles (EVs) into the circulating blood.
- Children with recurrent brain tumours or newly diagnosed diffuse intrinsic pontine gliomas are being enrolled in the first study to examine the efficacy of a drug that inhibits an enzyme called indoleamine 2,3 dioxygenase, which these tumours use to protect themselves from the child's natural immune response.
- A research study of tumour samples from patients with the rare genetic syndrome neurofibromatosis type 1 has uncovered new molecular clues about which tumours are most likely to be aggressive.
- A new study from the University of Pennsylvania has demonstrated that glioblastoma patients with a higher concentration of cell-free DNA (“cfDNA”) have a shorter progression-free survival following diagnosis when they are compared to patients with less cfDNA.
Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to nearly 6,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News every month by registering here.
To see an archive of existing e-News issues, click here.